Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19

Version 1 : Received: 16 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (13:02:03 CEST)

A peer-reviewed article of this Preprint also exists.

Abstract

The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven the biomedical community to action – to uncover and develop anti-viral interventions. One potential therapeutic approach currently being evaluated in numerous clinical trials is the agent remdesivir, which has endured a long and winding developmental path. Remdesivir is a nucleotide analog prodrug that perturbs viral replication, originally evaluated in clinical trials to thwart the Ebola outbreak in 2014. Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of its mechanism of action, discovery, and the current studies exploring its clinical effectiveness.

Keywords

SARS-CoV-2; COVID-19; coronavirus; remdesivir

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Comments (2)

Comment 1
Received: 6 May 2020
Commenter: Jacob Roth
Commenter's Conflict of Interests: I am a co-author.
Comment: Thank you for visiting the site and considering our work - this preprint has been published as the following "Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19" here in ACS Central Science: https://pubs.acs.org/doi/10.1021/acscentsci.0c00489#.XrDRs1PUgBY.twitter with DOI: 10.1021/acscentsci.0c00489
+ Respond to this comment
Comment 2
Received: 8 May 2020
Commenter: Jacob Roth
The commenter has declared there is no conflict of interests.
Comment: Thank you for considering our work - this article was published in ACS Central Science here: https://pubs.acs.org/doi/10.1021/acscentsci.0c00489.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 2
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.